<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269163</url>
  </required_header>
  <id_info>
    <org_study_id>2004C009G</org_study_id>
    <nct_id>NCT02269163</nct_id>
  </id_info>
  <brief_title>A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG</brief_title>
  <acronym>IGIV</acronym>
  <official_title>A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children With PID</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProMetic BioTherapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProMetic BioTherapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability,
      Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous
      (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases (PIDD) to assess
      the tolerability, safety, efficacy and pharmacokinetics of ProMetic's IGIV in subjects with
      PIDD. IGIV is intended for the treatment of children and adults with Primary Immunodeficiency
      Diseases (PIDD) who require IgG (Immunoglobulin G) replacement therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the rate of clinically documented serious bacterial infections (SBIs) in subjects treated with IMP to achieve a rate of less than one per year.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Primary Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Group 1 - Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 (adult) will enroll approximately 5 subjects aged ≥ 17-80 years to obtain 5 evaluable subjects. The first IMP infusion of Immune Globulin (Human) Intravenous, in the first five subjects will be staggered at 2-week intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the 5 subject of Cohort 1 have been fully evaluated, Cohort 2 will enroll approximately 10 subjects to obtain 10 evaluable subjects who will receive Immune Globulin (Human) Intravenous.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Adults and Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will include adult and children that may start with Commercial Immune Globulin Intravenous, as per Investigator until Cohort 1 and 2 have been evaluated and then Cohort 3 will start receiving IMP, Immune Globulin (Human) Intravenous.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin (Human) Intravenous</intervention_name>
    <description>ProMetic BioTherapeutics Immune Globulin Intravenous is a 10% liquid formulation of human IgG in 50 mL vials containing 100 mg/mL of IgG.</description>
    <arm_group_label>Group 1 - Adults</arm_group_label>
    <arm_group_label>Group 2 - Adults</arm_group_label>
    <arm_group_label>Group 3 - Adults and Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Commercial Immune Globulin Intravenous</intervention_name>
    <arm_group_label>Group 3 - Adults and Children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is male or female between the ages of 2 and 80 years at Screening.

               -  For Russian sites, only subjects 18 years of age and older, treated with
                  commercially licensed immune globulin product will be enrolled.

               -  For Cohort 1, all subjects will be aged ≥17 to 80 years.

               -  For Cohort 2, subjects will be aged 2 to &lt;17 years

          2. Subject or parent(s)/legal guardian has given written informed consent/assent (as
             applicable). Pediatric subjects are defined as 2 to 17 years of age at study entry and
             will require assent forms as appropriate.

          3. Subject or parent(s)/legal guardian agrees to comply with the requirements of the
             protocol.

          4. Female subjects of childbearing potential must have a negative urine pregnancy test
             documented at the visit which they receive the first infusion of IMP and must agree to
             employ adequate birth control measures, as determined by their IRB/IEC, for the
             duration of the study.

          5. The subject must have established one of the following three diagnoses (isolated PIDD
             of other types will be excluded):

               -  Common variable immunodeficiency (CVID)

               -  X-linked agammaglobulinemia (XLA)

               -  Hyper-IgM syndrome and documented low IgG levels (&lt;4.5 mg/mL [450 mg/dL]).

          6. Subjects must have been treated with a stable dose of immune globulin administered
             intravenously (IGIV) or subcutaneously (IGSC), as defined below.

               -  For IGIV, a stable dose is defined as administration of a dose of 200-800 mg/kg
                  with no more than 25% change during at least 3 consecutive treatments at 21-day
                  (±4 days) or 28-day (±4 days) dosing intervals.

               -  For IGSC, a stable dose is defined as administration of a dose of 300-900
                  mg/kg/month IV (or Sub-cutaneous equivalent), regardless of dosing schedule, with
                  no more than 25% change during at least 12 weeks.

          7. Subjects who are receiving IGSC when they enter the study must have received at least
             one previous documented IGIV infusion without an associated serious adverse event.

          8. Documented trough or steady state levels

               -  Subjects who are receiving IGIV when they enter the study have at least 2
                  documented serum IgG trough levels of ≥ 5 mg/ mL measured in the prior 6 months.
                  One of these can be the serum IgG level at Screening.

               -  Subjects who are receiving IGSC have at least 2 documented serum IgG steady state
                  levels of ≥ 5 mg/mL in the prior 24 weeks. One of these can be the serum IgG
                  level at Screening.

          9. Authorization to access personal health information.

        Exclusion Criteria:

          1. Subject has secondary immunodeficiency or has been diagnosed with dysgammaglobulinemia
             or isolated IgG subclass deficiency.

          2. Subject has ever had a history of severe anaphylactic or anaphylactoid reaction to
             immunoglobulins or other blood products.

          3. Subject has a known history of immunoglobulin A (IgA) deficiency and known anti-IgA
             antibodies. (Note that subjects with IgA deficiency without known antibodies to IgA
             may be enrolled.)

          4. Subject has had a thrombotic event, such as deep vein thrombosis, myocardial
             infarction, cerebrovascular accident, pulmonary embolism, at any time.

          5. Subject has received blood products except IGIV, IGSC, or albumin within the previous
             12 months.

          6. Subject has participated in another study (except for IGIV, IGSC studies) within the
             previous 4 weeks.

          7. Subject has had cancer in the past 5 years, except for basal cell or squamous cell
             cancers of the skin.

          8. Subject has current or prior diagnosis of malignancies of lymphoid cells such as
             lymphocytic leukemia, non-Hodgkin's lymphoma, or immunodeficiency with thymoma.

          9. Subject has known hypoalbuminemia (&lt;3 gm/dL), protein-losing enteropathy, or nephrotic
             syndrome.

         10. Subject has had a documented active infection within 7 days prior to Screening, or
             subject is on continuous prophylactic antibiotics. Subjects receiving a course of
             antibiotic treatment for a recent bacterial infection, which is controlled, can be
             enrolled into the study.

         11. Subject is positive for human immunodeficiency virus (HIV)-1 or HIV-2.

         12. Subject has a positive hepatitis C virus (HCV) or hepatitis B virus (HBV) nucleic acid
             test (NAT) performed either by qualitative or quantitative polymerase chain reaction
             (PCR) in the past 12 months.

         13. Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) &gt;2.5 times the upper limit of normal (ULN).

         14. Subject has serum creatinine &gt;1.5 times the ULN or a severe chronic condition such as
             renal failure with proteinuria.

         15. Subject has anemia with a hemoglobin level ≤8 g/dL.

         16. Subject has severe neutropenia with neutrophil count ≤1000 per mm3 or has lymphopenia
             with &lt;500 per/ mm3.

         17. Subject is taking prednisone at a dose ≥0.15 mg/kg/day. (Topical steroids for skin
             conditions, steroid eye drops, chronic use of inhaled steroids for asthma, and
             intranasal steroids for rhinitis are allowed.) Exception: A brief course of systemic
             steroids above this threshold (i.e., a steroid burst) is allowed for treatment of a
             short-term condition such as an asthma exacerbation or poison ivy exposure.

         18. Subject is receiving other immunosuppressive drugs or chemotherapy.

         19. Subject has known atrial fibrillation requiring anticoagulant therapy; congestive
             heart failure (New York Heart Association Class III/IV); cardiomyopathy; or cardiac
             arrhythmia associated with thromboembolic events, unstable or advanced ischemic heart
             disease, or hyperviscosity.

         20. Subject has known decreased Protein C and/or Protein S levels.

         21. Subject is positive for antibodies to β2GPI and/or β2GPI-DI at Screening.

         22. Female subject who is pregnant, breast-feeding, or planning a pregnancy during the
             course of the study.

         23. A history of epilepsy or multiple episodes of migraine (defined as at least one
             episode within 6 months of enrolment) not completely controlled by medication, or any
             condition that is likely to interfere with evaluation of the IMP or satisfactory
             conduct of the study in the Investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Moy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amber Shroeder, CCRA</last_name>
    <phone>434-483-5261</phone>
    <email>aschroeder@atlanticresearchgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deeba Sultani</last_name>
      <phone>949-824-2032</phone>
      <email>dsultani@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Sudhir Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asal Gharib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney Brown</last_name>
      <phone>323-361-4537</phone>
      <email>sybrown@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Church, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peck Y Ong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Tam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald M Ferdman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immunoe International Research</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayan Silkoff</last_name>
      <phone>303-773-9000</phone>
      <email>msilkoff@immunoe.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Melamed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Testory, MD., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin P O'Brien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edan Sarid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Hancock</last_name>
      <phone>303-398-1196</phone>
      <email>HancockC@NJHealth.org</email>
    </contact>
    <investigator>
      <last_name>Erwin Gelfand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Abbott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergy Associate of the Palm Beaches</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Farnan</last_name>
      <phone>561-626-4561</phone>
      <email>latallergy@aol.com</email>
    </contact>
    <investigator>
      <last_name>Mark Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Koterba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Trotter</last_name>
      <phone>727-553-1259</phone>
      <email>jtrotte1@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Duff, ARNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Leiding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Li</last_name>
      <phone>312-942-6176</phone>
      <email>jia_li@rush.edu</email>
    </contact>
    <investigator>
      <last_name>James Moy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Yu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed El-Isa, MD</last_name>
      <phone>260-483-4433</phone>
      <email>ahmedelisa@aol.com</email>
    </contact>
    <investigator>
      <last_name>Taki Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy P Sanders</last_name>
      <phone>314-268-4014</phone>
      <email>wendy_sanders@ssmhc.com</email>
    </contact>
    <investigator>
      <last_name>Bradley A Becker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan P Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Pinero</last_name>
      <phone>919-684-2281</phone>
      <email>gloria.pinero@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Amy P Stallings, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph L Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Padron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Tang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renee Kleris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Baloh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Kim-Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Debra Sedlak, PNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Lugar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary L Markert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John W Sleasman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimed Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren McNulty</last_name>
      <phone>614-430-8022</phone>
      <email>lauren@optimed.com</email>
    </contact>
    <contact_backup>
      <last_name>Ann Urbank, CNP</last_name>
      <phone>614-430-8022</phone>
      <email>ann@optimed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald McNeil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Urbank, MS., CNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Allergy Immunology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Martin</last_name>
      <phone>972-566-6801</phone>
      <email>rlmartin@allergypartners.com</email>
    </contact>
    <investigator>
      <last_name>Richard Wasserman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert W Sugerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine / Texas Children's Cancer and Hematology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Barrera</last_name>
      <phone>832-824-4209</phone>
      <email>dxbarrer@texaschildren.org</email>
    </contact>
    <investigator>
      <last_name>Feliz Seeborg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma, Allergy and Immunology Clinic</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Elkayam</last_name>
      <phone>360-733-5733</phone>
      <email>jselkayam@hinet.org</email>
    </contact>
    <investigator>
      <last_name>David Elkayam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

